MEDRx Co., Ltd.
Yonehiro Matsumura, President & CEO
Stock code: 4586, TSE Mothers

News Release Dated January 29, 2018

The Completion of a repeat dose pharmacology study for CPN-101 (previously MRX-4TZT)

MEDRx is pleased to announce the completion of a repeat dose pharmacology study for CPN-101 (previously MRX-4TZT), a transdermal patch formulation of Tizanidine*1 for the management of spasticity.

The product is being co-developed with Cipla*2 USA Inc. who in-licensed the worldwide marketing rights (excluding East Asia) on April 6th 2017.

The study met its predefined criteria and the product will now be advanced into the next stage of clinical development.

*Reference*

*1 Tizanidine
Tizanidine is a type of central analgesic (acts on the central nerves in the brain and the spinal cord to relieve muscle tonicity). This drug is used to alleviate discomfort from shoulder stiffness, back problems, frozen shoulder, tension headaches and other problems.

*2 Cipla
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally. Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems. After bolstering its US generics business through two acquisitions last year, Cipla is now actively foraying into the US branded specialty space through a blend of in-house innovation and inorganic efforts.

About Cipla USA
Through a comprehensive partnership model approach, Cipla has been dedicated to providing access to medicines at an affordable price for over 30 years in the US. Cipla USA own label was launched in January 2015. Cipla has executed over 20 US partnerships and currently has commercialized products in the US. The Company has supported the development of more than 170 ANDAs. Cipla USA brings a variety of technologies to the US markets in order to keep its ongoing commitment to provide access to high quality complex products at affordable prices.